| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2002.07.004 |
| P698 | PubMed publication ID | 11919250 |
| P50 | author | Valérie Letscher-Bru | Q115583690 |
| Shanti Natarajan-Amé | Q115583735 | ||
| Raoul Herbrecht | Q37841047 | ||
| P2093 | author name string | Patrick Dufour | |
| Ermanno Candolfi | |||
| Patrick Lutz | |||
| France Campos | |||
| Jocelyn Waller | |||
| Bruno Lioure | |||
| Jean-Pierre Bergerat | |||
| Odile Villard | |||
| Corina Oprea | |||
| Kun-Lun Liu | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| aspergillosis | Q259626 | ||
| invasive aspergillosis | Q3625278 | ||
| P304 | page(s) | 1898-1906 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients | |
| P478 | volume | 20 |
| Q40427463 | 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. |
| Q45277411 | A comparison of galactomannan-ELISA and a newly developed galactomannan-LATEX test in the serologic diagnosis of invasive aspergillosis in patients with hematologic malignancies |
| Q40517539 | A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients |
| Q56837297 | Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q35838440 | Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients |
| Q36774247 | Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders |
| Q38484090 | Antibody testing in aspergillosis--quo vadis? |
| Q35058091 | Antifungal pharmacotherapy for invasive mould infections |
| Q46503389 | Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay |
| Q37873552 | Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy |
| Q44773560 | Antigen detection in invasive aspergillosis and candidosis: the Austrian experience |
| Q38066612 | Application of diagnostic markers to invasive aspergillosis in children |
| Q41653776 | Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization |
| Q36094242 | Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing |
| Q37702655 | Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid |
| Q37101166 | Aspergillus tracheobronchitis causing subtotal tracheal stenosis in a liver transplant recipient |
| Q51608149 | Bronchoalveolar galactomannan in invasive pulmonary aspergillosis: a prospective study in pediatric patients. |
| Q40671481 | Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements |
| Q43198289 | Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q38737982 | Chronic Meningitis: Simplifying a Diagnostic Challenge |
| Q40404487 | Clinical and laboratory signs as dengue markers during an outbreak in Rio de Janeiro |
| Q53552170 | Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? |
| Q54671227 | Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. |
| Q51617424 | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. |
| Q35049005 | Clinical utility and development of biomarkers in invasive aspergillosis |
| Q53167712 | Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies |
| Q76381447 | Combination antifungal therapy |
| Q39803414 | Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate |
| Q81924114 | Comparison of the value of measurement of serum galactomannan and Aspergillus-specific antibodies in the diagnosis of canine sino-nasal aspergillosis |
| Q46897118 | Computed tomography guided percutaneous lung biopsies and suspected fungal infections in pediatric cancer patients |
| Q36357893 | Current approaches to diagnosis and treatment of invasive aspergillosis |
| Q35782538 | Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies. |
| Q36900157 | Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens |
| Q37833638 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies |
| Q24533425 | Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments |
| Q34990623 | Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis |
| Q35789251 | Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis |
| Q37576198 | Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction |
| Q53746276 | Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. |
| Q37317965 | Development and evaluation of enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification for diagnosis of invasive aspergillosis |
| Q33338675 | Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid |
| Q34952419 | Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis |
| Q35137391 | Development and validation of an HPLC-MS/MS method for the early diagnosis of aspergillosis |
| Q34990441 | Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients |
| Q39990268 | Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples |
| Q38088858 | Diagnosing invasive fungal diseases - limitations of microbiological diagnostic methods |
| Q37463228 | Diagnosis and treatment of aspergillosis in children |
| Q34514484 | Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis |
| Q35597097 | Diagnosis of invasive aspergillosis: recent developments and ongoing challenges |
| Q40524695 | Diagnosis of invasive fungal diseases in pediatric patients |
| Q37777195 | Diagnosis of invasive fungal infections in immunocompromised children |
| Q38474613 | Diagnosis of invasive fungal infections using real-time PCR assay in paediatric acute leukaemia induction |
| Q44183804 | Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan |
| Q37854718 | Diagnostic methods for fungal infections in pediatric patients: microbiological, serological and molecular methods |
| Q36584898 | Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies |
| Q37934487 | ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients |
| Q34052696 | Early Diagnosis of Invasive Aspergillosis in Neutropenic Patients. Comparison between Serum Galactomannan and Polymerase Chain Reaction |
| Q40489288 | Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin |
| Q37788797 | Epidemiology of invasive fungal infections in neonates and children |
| Q36328397 | Evaluation of pulmonary infiltrates in patients after stem cell transplantation |
| Q46977790 | Evaluation of serum galactomannan detection for diagnosis of feline upper respiratory tract aspergillosis |
| Q80552968 | False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam |
| Q39755727 | False-positive results by the platelia Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate |
| Q37739908 | Fungal infections after hematopoietic stem cell transplantation |
| Q36382582 | Fungal infections in bone marrow transplant recipients |
| Q36841586 | Fungal infections in primary immunodeficiencies |
| Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
| Q36851160 | Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients |
| Q59308866 | Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies |
| Q49612984 | Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis |
| Q40497134 | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study |
| Q36691715 | Galactomannan antigen detection in the diagnosis of invasive aspergillosis |
| Q81785456 | Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis |
| Q24186895 | Galactomannan detection for invasive aspergillosis in immunocompromised patients |
| Q24240734 | Galactomannan detection for invasive aspergillosis in immunocompromized patients |
| Q53653935 | Galactomannan detection in computerized tomography‐based broncho‐alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis |
| Q83131195 | Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients |
| Q30244009 | Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q81305176 | High rate of discordance between clinical and autopsy diagnoses in blood and marrow transplantation |
| Q35568846 | How to treat fungal infections in ICU patients |
| Q43995112 | IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. |
| Q44023091 | Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign |
| Q26766376 | Imaging fungal infections in children |
| Q40263137 | Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study |
| Q35587105 | Impact of diagnostic markers on early antifungal therapy |
| Q36539727 | Improved detection of circulating Aspergillus antigen by use of a modified pretreatment procedure |
| Q42382713 | Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit |
| Q35557446 | Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment |
| Q40531014 | Infections under immunosuppressive therapy following organ transplantation |
| Q44144158 | Invasive Aspergillus infections in allo-SCT recipients: environmental sampling, nasal and oral colonization and galactomannan testing |
| Q37954958 | Invasive aspergillosis in children with acquired immunodeficiencies |
| Q36403666 | Invasive aspergillosis in children with hematologic malignancies |
| Q37854719 | Invasive aspergillosis in children with hematological malignancies |
| Q37854721 | Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation |
| Q36235159 | Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia. |
| Q38066616 | Invasive aspergillosis in the intensive care unit |
| Q40397551 | Invasive aspergillosis of the small bowel in an infant with acute myeloid leukemia and intestinal obstruction |
| Q57208471 | Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q81434718 | Invasive mycoses in children receiving hemopoietic SCT |
| Q33271183 | Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series |
| Q40355575 | Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy |
| Q36242300 | Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis |
| Q89782807 | Isolation, Molecular Identification, and Mycotoxin Production of Aspergillus Species Isolated from the Rhizosphere of Sugarcane in the South of Iran |
| Q36267587 | Laboratory diagnosis of invasive aspergillosis. |
| Q37287794 | Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome |
| Q38008251 | Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach |
| Q37543967 | Long term outcome of medical and surgical co-management of craniospinal aspergillosis in an immunocompromised patient |
| Q36087577 | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients |
| Q38227595 | Mold infections of the central nervous system |
| Q36774252 | Molecular and serological diagnosis of invasive aspergillosis: new answers to old questions? |
| Q84129363 | Mucositis does not lead to false-positivity of the Platelia Aspergillus enzyme-linked immunosorbent assay |
| Q64228957 | New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies |
| Q35561985 | New approaches to invasive fungal infections |
| Q34430636 | Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. |
| Q43975147 | Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis |
| Q49612998 | Pediatric Invasive Aspergillosis |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q36434278 | Prognosis of invasive pulmonary aspergillosis in patients with hematologic diseases in Korea. |
| Q51999514 | Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. |
| Q54723179 | Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematolog |
| Q80174046 | Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological |
| Q33662384 | Pulmonary aspergillosis as opportunistic mycoses in a cohort of human immunodeficiency virus-infected patients: Report from a tertiary care hospital in North India |
| Q40771905 | Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole |
| Q35917383 | Recent advances in antifungal pharmacotherapy for invasive fungal infections |
| Q28077381 | Recent developments in the management of invasive fungal infections in patients with oncohematological diseases |
| Q34750351 | Recent progress in the diagnosis of fungal infections in the immunocompromised host. |
| Q34042178 | Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories |
| Q46775309 | Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q41996456 | Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children |
| Q40258864 | Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies |
| Q35200641 | Specific infectious complications after stem cell transplantation |
| Q80510576 | Supportive care |
| Q38508539 | The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients |
| Q38679742 | Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses |
| Q36780873 | Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis |
| Q33900089 | Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. |
| Q42911728 | Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiary-care center over a 12-month period |
| Q35951605 | Utility of Aspergillus antigen detection in specimens other than serum specimens |
| Q37302104 | Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia |
| Q38089915 | Utility of galactomannan antigen detection in bronchoalveolar lavage fluid in immunocompromised patients |
| Q37051568 | Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients |
| Q40508195 | Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. |
| Q36452307 | Well-characterized monoclonal antibodies against cell wall antigen of Aspergillus species improve immunoassay specificity and sensitivity |
| Q81038041 | [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia] |
| Q75389642 | [Guidelines for fungal diagnoses and antifungal sensitivity studies] |
Search more.